SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Guerin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)

被引：4
|
作者：
Necchi, A. [1 ]
Catto, J. W. F. [2 ]
Powles, T. B. [3 ]
Guerrero-Ramos, F. [4 ]
Simone, G. [5 ]
Shore, N. D. [6 ]
Salinas, J. [7 ]
Merseburger, A. S. [8 ]
Roumiguie, M. [9 ]
Kitamura, H. [10 ]
Morris, D. [11 ]
Wei, Q. [12 ]
Korkes, F. [13 ]
Hasan, M. [14 ]
Jin, S. [15 ]
Maffeo, J. [15 ]
Hammond, C. [14 ]
Sweiti, H. [14 ]
Somer, R. [14 ]
Chang, S. S. [16 ]
机构：
[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp & Sci Inst, Dept Med Oncol, Milan, Italy
[2] Univ Sheffield, Sch Med, Urol Dept, Sheffield, S Yorkshire, England
[3] Queen Mary Univ London, Dept Med Oncol, Barts Canc Ctr, London, England
[4] 12 Octubre Univ Hosp, Dept Urol, Madrid, Spain
[5] IRCCS, Regina Elena Natl Canc Inst, Dept Oncol, Rome, Italy
[6] Carolina Urol Res Ctr, Surg & Oncol Dept, Myrtle Beach, SC USA
[7] CEMAIC Private Med Ctr, Dept Oncol, Cordoba, Argentina
[8] Univ Hosp Schleswig Holstein, Dept Urol, Campus Lubeck, Lubeck, Germany
[9] Inst Univ Canc Toulouse Oncopole CHU, Dept Oncol, Toulouse, France
[10] Toyama Univ, Grad Sch Med & Pharmaceut Sci Res, Dept Urol, Toyama, Japan
[11] Urol Associates PC, Dept Urol, Nashville, TN USA
[12] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China
[13] Hosp Albert Einstein, Fac Med ABC, Dept Urol, Santo Andre, SP, Brazil
[14] Janssen Res & Dev, Res & Dev, Spring House, PA USA
[15] Janssen Res & Dev, Res & Dev, Lexington, MA USA
[16] Vanderbilt Univ, Med Ctr, Dept Urol, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2825
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2407TiP
引用
收藏
页码：S1224 / S1224
页数：1
相关论文
共 50 条
  • [1] SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette-Guerin in patients with BCG-naive high-risk non-muscle-invasive bladder cancer
    Catto, J. W. F.
    Necchi, A.
    Powles, T.
    Guerrero-Ramos, F.
    Simone, G.
    Shore, N.
    Salinas, J. S.
    Merseburger, A. S.
    Roumiguie, M.
    Hiroshi, K.
    Morris, D. M.
    Qiang, W.
    Korkes, F.
    Hasan, M.
    Jin, S.
    Maffeo, J.
    Hammond, C.
    Sweiti, H.
    Somer, R. S.
    Chang, S. S.
    EUROPEAN UROLOGY, 2024, 85 : S1505 - S1505
  • [2] SAFETY AND TOLERABILITY OF TAR-200 MONOTHERAPY IN PATIENTS WITH BACILLUS CALMETTE-GUERIN (BCG)UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER (HR NMIBC) IN SUNRISE-1
    Siamak, Daneshmand
    Daniel, Zainfeld
    Christopher, Pieczonka
    Giuseppe, Simone
    Michiel, S. van der Heijden
    Martin, Bogemann
    David, S. Morris
    Philipp, Spiegelhalder
    Laurence, H. Belkoff
    Karel, Decaestecker
    Harm, Arentsen
    Shalaka, Hampras
    Christopher, J. Cutie
    Hussein, Sweiti
    Katharine, Stromberg
    Jason, Martin
    Abhijit, Shukla
    Joseph, M. Jacob
    Evanguelos, Xylinas
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [3] First-line Maintenance Therapy in Adult Patients with BCG-naive High-risk - non-muscle-invasive Bladder Cancer Open-label, multicenter, randomized Phase 3 Study to evaluate the Efficacy and Safety of TAR-200 in combination with Cetrelimab versus TAR-200 Monotherapy versus intravesical Bacillus Calmette-Guerin (BCG) in Patients with BCG-naive High-risk non-muscle-invasive Bladder Cancer (HR-NMIBC) - SUNRISE-3-AB 85/23 of AUO
    Rexer, H.
    Stenzl, A.
    Ohlmann, C. -H.
    UROLOGIE, 2024, 63 (01): : 135 - 136
  • [4] FIRST RESULTS FROM SUNRISE-1 IN PATIENTS WITH BCG UNRESPONSIVE HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER RECEIVING TAR-200 IN COMBINATION WITH CETRELIMAB, TAR-200, OR CETRELIMAB ALONE
    Daneshmand, Siamak
    van der Heijden, Michiel S.
    Jacob, Joseph M.
    Necchi, Andrea
    Xylinas, Evanguelos
    Morris, David S.
    Spiegelhalder, Philip
    Zainfeld, Daniel
    Kang, Taek Won
    Matulay, Justin T.
    Belkoff, Laurence H.
    Decaestecker, Karel
    Arentsen, Harm
    Hampras, Shalaka
    Jin, Shu
    Cutie, Christopher J.
    Sweiti, Hussein
    Stromberg, Katherine
    Martin, Jason
    Simone, Giuseppe
    JOURNAL OF UROLOGY, 2023, 209 : E1187 - E1187
  • [5] SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guerin who are ineligible for or elected not to undergo radical cystectomy
    van der Heijden, M. S.
    Cutie, C.
    Acharya, M.
    Stromberg, K.
    Li, X.
    Beeharry, N.
    Stewart, R.
    Maffeo, J.
    Indoria, C.
    Levin, W.
    Jacob, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S723 - S724
  • [6] TAR-200+/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette- Guerin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)
    van der Heijden, M. S.
    Simone, G.
    Boegemann, M.
    Xylinas, E.
    Roumiguie, M.
    Guerrero-Ramos, F.
    Necchi, A.
    Daneshmand, S.
    Van Praet, C.
    Spiegelhalder, P.
    Decaestecker, K.
    Arentsen, H.
    Zainfeld, D.
    Hampras, S.
    Cutie, C. J.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shukla, A.
    Jacob, J. M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1272 - 1273
  • [7] SunRISe-1: Phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to Bacillus Calmette-Guerin who are ineligible for or decline radical cystectomy.
    Van der Heijden, Michiel Simon
    Cutie, Christopher
    Hampras, Shalaka
    Indoria, Charu
    Stewart, Rachel
    Acharya, Milin
    Stromberg, Katherine
    Li, Xiang
    Beeharry, Neil
    Maffeo, John
    Jacob, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [8] Results from SunRISe-1 in patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer receiving TAR-200 monotherapy
    Necchi, A.
    Jacob, J. M.
    Daneshmand, S.
    Simone, G.
    Xylinas, E.
    Morris, D. S.
    Spiegelhalder, P.
    Zainfeld, D.
    Kang, T. W.
    Matulay, J. T.
    Belkoff, L. H.
    Decaestecker, K.
    Arentsen, H.
    Hampras, S.
    Cutie, C. J.
    Sweiti, H.
    Stromberg, K.
    Martin, J.
    Shulka, A.
    Van Der Heijden, M. S.
    EUROPEAN UROLOGY, 2024, 85 : S1508 - S1509
  • [9] SUNRISE-5: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF TAR-200 COMPARED WITH INTRAVESICAL CHEMOTHERAPY AFTER BACILLUS CALMETTE-GUERIN IN RECURRENT HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER
    Sima, Porten
    Sumeet, Bhanvadia
    Saltanat, Najmi
    Hussein, Sweiti
    John, Maffeo
    Kate, Stromberg
    Jovita, Gale
    Benjamin, Pradere
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2025, 43 (03)
  • [10] A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
    De Santis, Maria
    Abdrashitov, Ramil
    Hegele, Axel
    Kolb, Margaret
    Parker, Suzanne
    Redorta, Juan Palou
    Nishiyama, Hiroyuki
    Xiao, Feng
    Gupta, Ashok Kumar
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345